CD8A and neoplasm: Ipilimumab plus nivolumab increased the frequency of CD3+, CD3+CD8+, and CD3+CD8+CD45RO+ memory TILs in post-operative tumor samples compared to preoperative samples, whereas nivolumab monotherapy had no effect [125].